Skip to main content
. 2022 Aug 26;13:911801. doi: 10.3389/fgene.2022.911801

FIGURE 3.

FIGURE 3

Intratumoral heterogeneity of NSCLC. The TIDE test was used to predict response to immune checkpoint inhibition therapy.